Table 4.

Univariate and multivariate logistic regression analyses of host and viral predicting NAs therapy response factors in CHB patients.

	Analogues antiviral therapy		Univariate analysis		Multivariate analysis
	Responder (n=28)	Nonresponder (n=26)	OR (95% Cl)	p value	OR (95% Cl)	p value
Age (year)	43.4±1.98	54.4±3.51	0.95 (0.91–0.99)	0.013	0.90 (0.83–0.98)	0.011
Female gender	18	7	4.88 (1.49–16.04)	0.007	10.3 (1.60–65.81)	0.011
Baseline HBV viral load (kIU/ml)	13.702±8.385	57.857±15.205	0.999987 (0.99997–0.999998)	0.019	0.999961 (0.99993–0.99999)	0.008
Baseline HBeAg (reactive)	8	15	0.29 (0.09–0.90)	0.033
Baseline ALT (IU/l)	136±41	76±11	1.003 (0.998–1.009)	0.22	1.01 (0.99–1.02)	0.178
Previous NAs* therapy	15	12	1.35 (0.45–4.03)	0.586
Baseline drug resistance presence **	19	17	1.12 (0.36–3.47)	0.85
Liver biopsy inflammation activity#	2	2	1.42 (0.60–3.35)	0.41
Liver biopsy fibrosis stage#	1.5	1.5	0.93 (0.46–1.93)	0.86
ATA IL-10 haplotype	8	11	0.54 (0.18–1.69)	0.29
Immunocompetent patient	17	17	0.8 (0.25–2.59)	0.7	0.09 (0.009–0.93)	0.038

Data are presented as a mean value ± standard error (SE);

^#data presented as a median value;

^*nucleoside/nucleotide analogues;

^**the presence of HBV drug-resistant minor variant before NAs therapy.